What Is Paraganglioma? A Paraganglioma is a rare type of neuroendocrine tumor that arises from clusters of specialized nerve cells called paraganglia, which are part of the autonomic nervous system. These cells, known as chromaffin cells, normally produce hormones called catecholamines (like adrenaline and noradrenaline) that help regulate the body's response to stress and manage blood pressure. Paragangliomas can occur anywhere in the body outside of the adrenal glands. Similar tumors that develop inside the adrenal glands are called pheochromocytomas. While these tumors are often benign (non-cancerous), they can, in some cases, be malignant (cancerous) and spread to other parts of the body (metastasize). The effects they have on the body largely depend on the amount of hormones they secrete and the tumor's location. According to data from the World Health Organization (WHO), paragangliomas are quite rare, with an estimated annual incidence of about 2 to 8 cases per million people. However, it is believed that these figures may underestimate the true incidence due to undiagnosed or misdiagnosed cases. Although these tumors can appear at any age, they are most commonly diagnosed in individuals between the ages of 30 and 50. A significant portion, approximately 30-50% of paragangliomas, are associated with specific inherited gene mutations. For this reason, genetic counseling and testing are frequently recommended upon diagnosis. The rarity and complex nature of these tumors can make the diagnostic and treatment processes challenging, necessitating a multidisciplinary approach from a team of medical experts. The public health impact of paragangliomas stems from their potential for life-threatening complications. Tumors that secrete hormones can lead to serious cardiovascular problems, including uncontrolled high blood pressure (hypertension), heart attack, stroke, and arrhythmias. This situation is sometimes described as a "pharmacological time bomb" because a sudden release of hormones can trigger a hypertensive crisis. Tumors that do not secrete hormones can grow and press on surrounding tissues and nerves, causing symptoms such as pain, nerve damage, or organ dysfunction. For these reasons, the early diagnosis and proper management of paragangliomas are vital to prevent serious health issues and improve a patient's quality of life. **Tip:** It is important for patients diagnosed with a paraganglioma to receive genetic counseling to understand if there is a similar risk within their family. Early detection plays a critical role in managing the disease. What Are the Symptoms of Paraganglioma? The signs and symptoms of paraganglioma vary widely depending on whether the tumor secretes hormones (is functional), its size, and its location in the body. Symptoms can develop gradually or appear suddenly in episodes known as paroxysms. The most characteristic symptoms of functional paragangliomas are due to excessive catecholamine release. This triggers a classic "triad" of symptoms: headache, excessive sweating (diaphoresis), and palpitations (a rapid or irregular heartbeat). In addition to these, patients may experience severe anxiety, feelings similar to a panic attack, paleness of the face (pallor), tremors, and shortness of breath during these episodes. The attacks can last from a few minutes to over an hour and may be triggered by specific foods, medications, or physical activities. In cases of advanced or large tumors, the symptoms become more pronounced. Persistent high blood pressure may be resistant to standard treatments and can, over time, damage organs like the heart, kidneys, and brain. Non-functional paragangliomas, which do not secrete hormones, are often located in the head and neck region, and their symptoms are primarily caused by the tumor's mass effect. For example, a lump in the neck, difficulty swallowing, hoarseness, ringing in the ears (especially a pulsating type synchronized with the heartbeat, known as pulsatile tinnitus), hearing loss, or dizziness may occur. Large tumors in the abdomen can cause abdominal pain, a feeling of fullness, or digestive issues. When malignant (cancerous) paragangliomas spread to other parts of the body (bones, liver, lungs, lymph nodes), they produce symptoms specific to the area of metastasis, such as bone pain or shortness of breath. Correctly interpreting these symptoms is crucial for an early diagnosis. The table below summarizes the common symptoms seen in paraganglioma, their typical severity, frequency, and characteristics. The presence of one or more of these symptoms, especially if they occur in episodes, warrants a consultation with a healthcare professional. Early diagnosis and treatment are the most important steps in preventing potentially life-threatening complications. Symptom Severity Frequency Typical Characteristic High Blood Pressure (Hypertension) Moderate-Severe Common Can be sustained or in attacks (paroxysmal), often resistant to treatment. Headache Mild-Severe Common Usually throbbing and severe during attacks. Excessive Sweating Moderate-Severe Common Profuse sweating without an obvious cause, especially on the torso. Palpitations Moderate-Severe Common Sensation of a rapid, forceful, or irregular heartbeat. Anxiety and Panic Attack Sensation Mild-Severe Common Sudden onset of intense fear, a sense of impending doom, and restlessness. Facial Pallor Moderate Frequent Occurs during attacks due to constriction of blood vessels. Neck Mass Mild-Moderate Less Common (Location-Dependent) Usually a painless, slow-growing lump (especially in head & neck tumors). Pulsatile Tinnitus Mild-Moderate Rare (Location-Dependent) A humming or ringing sound in the ear that is in sync with the heartbeat. **EMERGENCY WARNING:** If you experience symptoms such as a sudden and severe headache, chest pain, extreme difficulty breathing, confusion, or signs of a stroke (facial drooping, weakness in an arm or leg), call emergency services immediately or go to the nearest emergency room. These could be signs of a hypertensive crisis. Causes of Paraganglioma The exact cause of a paraganglioma is not always clear, but it is understood that both genetic and environmental factors play a role in its development. Fundamentally, these tumors arise from the abnormal and uncontrolled proliferation of chromaffin cells within the paraganglia of the autonomic nervous system. What triggers this cellular division is not fully understood, but a significant portion of cases have an underlying genetic predisposition. Research shows that about 30% to 50% of all paraganglioma cases are caused by an inherited gene mutation. This makes paraganglioma one of the most heritable neuroendocrine tumors known. Because of this strong genetic link, genetic testing is often recommended for the patient and sometimes for their first-degree relatives upon diagnosis. Types and Classification of the Disease Paragangliomas can be classified in several ways, with the most common classification based on their origin within the autonomic nervous system: sympathetic and parasympathetic. Sympathetic paragangliomas are usually found in the abdomen and chest and are often functional, meaning they secrete catecholamines (adrenaline, noradrenaline). Therefore, they are more likely to cause the classic symptoms of hypertension, palpitations, and sweating. Parasympathetic paragangliomas, on the other hand, are typically located in the head and neck region (e.g., carotid body, jugular foramen) and are usually non-functional, meaning they do not secrete hormones. Their symptoms are more often due to the pressure the growing tumor exerts on surrounding structures. Additionally, paragangliomas are named based on their location, such as carotid body tumor, glomus jugulare tumor, or bladder paraganglioma. They are also classified as benign or malignant. A diagnosis of malignancy can only be confirmed by the presence of metastasis—the spread of the tumor to tissues where paraganglia are not normally found, such as the lungs, liver, or bone. Risk Factors The most significant risk factor for developing a paraganglioma is genetic predisposition. Mutations in certain genes dramatically increase the risk of these tumors. The most commonly associated genes are part of the succinate dehydrogenase (SDH) gene family (SDHA, SDHB, SDHC, SDHD, SDHAF2). In particular, SDHB gene mutations are associated with a higher risk of the paraganglioma being malignant and metastasizing. Other associated genetic syndromes include Von Hippel-Lindau (VHL) disease, Neurofibromatosis Type 1 (NF1), and Multiple Endocrine Neoplasia Type 2 (MEN2). Individuals with a family history of these syndromes or a history of paraganglioma/pheochromocytoma are at high risk. Besides genetic factors, there is some evidence that chronic hypoxia (low oxygen levels) may be a risk factor. For instance, people living at high altitudes or those with conditions like chronic obstructive pulmonary disease (COPD) may have an increased incidence of paragangliomas, especially carotid body tumors. However, in the majority of cases, no clear risk factor is identified, and the tumor develops "sporadically." Prevention or Management Strategies for Paraganglioma There is no known definitive primary prevention method to stop paragangliomas from developing, as a majority of cases either arise sporadically or are based on a strong genetic foundation. Therefore, efforts are focused not on prevention but on screening high-risk individuals and managing the disease effectively through early detection. The most significant risk group consists of individuals who carry gene mutations associated with hereditary paraganglioma syndromes (VHL, MEN2, NF1, SDH mutations). For these individuals, regular medical follow-up and screening programs are vital. These programs aim to detect the disease using early diagnosis methods for paraganglioma before it causes symptoms or leads to complications, ensuring timely intervention. For individuals at risk, management strategies typically begin with genetic counseling. Genetic testing can confirm the presence of a specific mutation, and this information allows for a risk assessment for both the patient and their family members. In the case of a positive genetic result, doctors recommend periodic screenings. These screenings usually include annual blood and urine tests (to measure plasma or urinary metanephrine levels) and imaging tests (like MRI or CT scans) at regular intervals. This proactive approach allows for the detection of tumors when they are very small and more easily treatable. Furthermore, symptoms like high blood pressure should be closely monitored in these patients, and any suspicious symptoms should be reported to a doctor immediately. This strategy is the most effective way to keep the disease's progression under control and maintain a high quality of life. Research into the prevention and management of paragangliomas is ongoing. Studies aimed at understanding the molecular mechanisms of genetically-based tumors hold promise for the development of targeted preventive therapies in the future. For example, research is being conducted on drugs that could correct the metabolic pathway disruptions caused by SDH mutations. Additionally, advances in imaging technology are leading to more sensitive and less invasive screening methods. Functional imaging techniques (such as Ga-68 DOTATATE PET/CT) have the potential to detect tumors at a very early stage with high accuracy. Such research holds the promise of making paraganglioma management more personalized and effective in the future. Risk Groups and Special Situations Although paraganglioma can occur at any age and in any gender, certain populations are at higher risk or may experience a different disease course. The most distinct risk group includes individuals carrying gene mutations associated with hereditary paraganglioma syndromes. In these individuals, tumors tend to appear at a younger age, be multiple (multifocal), and occur on both sides of the body (bilateral). Those with an SDHB gene mutation, in particular, face a significantly higher risk of malignancy and metastasis. Therefore, patients with this genetic predisposition require careful and regular lifelong monitoring. While paragangliomas in children are rare, nearly all such cases have an underlying genetic cause, making comprehensive genetic investigation essential. Pregnancy presents a special challenge for paraganglioma management. A paraganglioma diagnosed during pregnancy carries serious risks for both the mother and the fetus. The high levels of catecholamines released from the tumor can lead to uncontrolled hypertension, preeclampsia, placental abruption, fetal growth restriction, and even maternal or fetal death. The management of paraganglioma in pregnancy must be carefully planned by a multidisciplinary team consisting of an endocrinologist, surgeon, anesthesiologist, and obstetrician. Treatment usually begins with alpha-blocker medications to control blood pressure, and the optimal timing for tumor removal (often in the second trimester or after delivery) is determined. Going into labor with an undiagnosed paraganglioma is extremely dangerous due to the massive catecholamine surge that can be triggered by the stress of labor. Elderly patients also represent a special case. The diagnosis of paraganglioma in this population may be delayed because the symptoms can be mistaken for other common age-related health issues, such as essential hypertension or anxiety disorders. Furthermore, the additional comorbidities (such as heart disease or kidney failure) often present in older patients can make treatment options, especially surgery, riskier. Therefore, when making a treatment decision for an elderly patient, their overall health status, life expectancy, and the potential benefits and risks of the treatment must be carefully evaluated. In some cases, less invasive approaches or medical therapy aimed solely at controlling symptoms may be preferred over surgery. For each of these special groups, individualizing the treatment and follow-up plans is essential to achieve the best outcomes. Treatment Methods and Medications for Paraganglioma The treatment for paraganglioma is a complex process requiring a multidisciplinary approach and is planned individually based on many factors, including the tumor's size, location, hormone-secreting status (functional or not), potential for malignancy, and the patient's overall health. The primary goal of treatment is to completely remove the tumor if possible, control the symptoms caused by excess hormones, and prevent potential complications. Treatment options include surgery, medication, radiotherapy, and targeted therapies. The first-line and most effective curative treatment is the complete surgical removal of the tumor. Before surgical intervention, careful preparation of the patient, especially those with hormone-secreting (functional) tumors, is critically important. During surgery, manipulation of the tumor can trigger a sudden and massive release of catecholamines, leading to a life-threatening hypertensive crisis (an extreme spike in blood pressure). To prevent this, medication is started as part of the preoperative preparation for paraganglioma surgery at least 7-14 days before the operation. The most commonly used drugs for this preparation are alpha-blockers, which relax blood vessels to lower blood pressure. Beta-blockers may be added later to control the heart rate. For tumors in the head and neck or in hard-to-reach locations, procedures like embolization may be performed before surgery to reduce blood flow to the tumor. Surgery should be performed by an experienced team, as these tumors are often in close proximity to major blood vessels and nerves. Other treatment methods are employed when the tumor cannot be completely removed surgically, has metastasized, or when the patient is at high risk for surgery. These methods and commonly used drugs include: - Radiotherapy (Radiation Therapy): Used particularly for tumors in the head and neck that are not suitable for surgery or for residual tumors after surgery. Focused radiation techniques like Stereotactic Radiosurgery (SRS) can control tumor growth without damaging surrounding tissues. - Metaiodobenzylguanidine (MIBG) Therapy: This is a type of targeted radionuclide therapy. MIBG is a substance absorbed by paraganglioma cells. By attaching radioactive iodine (I-131) to MIBG, radiation can be delivered directly to the tumor cells, destroying them. This treatment is an option, especially for metastatic paragangliomas. - Chemotherapy: Conventional chemotherapy is generally reserved for aggressive and rapidly progressing metastatic paragangliomas. Various drug combinations can be used, but success rates vary. - Targeted Therapies: In recent years, new drugs have been developed that target specific molecular pathways that enable tumor growth. Tyrosine kinase inhibitors like Sunitinib or Belzutifan have shown promising results for advanced paragangliomas, especially those associated with genetic syndromes or those that do not respond to other treatments. Belzutifan is a HIF-2α inhibitor that is particularly effective for tumors associated with VHL syndrome. Diseases Similar to Paraganglioma Paragangliomas, especially when they secrete hormones, can cause a wide variety of symptoms that overlap with many other common health problems. This makes them prone to being confused with other conditions during the diagnostic process, a situation known as differential diagnosis. Reaching the correct diagnosis requires carefully ruling out these other possibilities. For example, the episodic nature of the symptoms can be mistaken for panic disorder or anxiety attacks. The persistent high blood pressure might be misdiagnosed as essential hypertension, a condition affecting millions. Other potential confusions include thyrotoxicosis (excess thyroid hormone), cardiac arrhythmias, and even menopausal symptoms. The condition most frequently confused in a differential diagnosis is the pheochromocytoma, often called the "sister tumor" of paraganglioma. In fact, both are neuroendocrine tumors arising from the same cell type (chromaffin cells). The key difference is their location: pheochromocytomas are located within the adrenal glands (adrenal medulla), while paragangliomas develop outside of them. Their symptoms and diagnostic approaches are nearly identical. The following table compares paraganglioma with some of the conditions it is most commonly mistaken for. Disease Similar Symptoms Distinguishing Features Pheochromocytoma High blood pressure, headache, sweating, palpitations, anxiety (symptoms are nearly identical). The main difference is location. Pheochromocytoma is in the adrenal gland; paraganglioma is outside of it. The diagnosis is confirmed with imaging. Essential Hypertension Sustained high blood pressure. In paraganglioma, blood pressure is often episodic (paroxysmal), more volatile, and responds poorly to standard blood pressure medications. Metanephrine tests are normal in essential hypertension. Panic Disorder / Anxiety Sudden attacks of palpitations, sweating, trembling, shortness of breath, fear of dying. Paraganglioma attacks are usually associated with severe headache and a spike in blood pressure. Metanephrine levels are elevated during or after an attack. Hyperthyroidism (Thyrotoxicosis) Palpitations, sweating, nervousness, weight loss, heat intolerance. In hyperthyroidism, thyroid hormones (T3, T4) are high and TSH is low. Physical findings like a goiter are often present. Making the correct diagnosis can be life-saving, as an untreated paraganglioma can lead to severe cardiovascular complications. Therefore, the differential diagnosis process must be conducted meticulously in patients with suspicious symptoms.
Read the full article
